MA37619A1 - Anticorps anti-fcrn - Google Patents

Anticorps anti-fcrn

Info

Publication number
MA37619A1
MA37619A1 MA37619A MA37619A MA37619A1 MA 37619 A1 MA37619 A1 MA 37619A1 MA 37619 A MA37619 A MA 37619A MA 37619 A MA37619 A MA 37619A MA 37619 A1 MA37619 A1 MA 37619A1
Authority
MA
Morocco
Prior art keywords
fcrn antibodies
formulations
fcrn
antibodies
dna
Prior art date
Application number
MA37619A
Other languages
Arabic (ar)
English (en)
Other versions
MA37619B1 (fr
Inventor
Helene Margaret Finney
Alastair David Griffiths Lawson
Stevan Graham Shaw
Bryan John Smith
Kerry Louise Tyson
Lara Kevorkian
Christoph Meier
Kaushik Sarkar
Paul Alan Atherfold
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46458733&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37619(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of MA37619A1 publication Critical patent/MA37619A1/fr
Publication of MA37619B1 publication Critical patent/MA37619B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)

Abstract

L'invention concerne des anticorps spécifiques de fcrn, des formulations les comprenant, l'utilisation de chacun en thérapie, des procédés d'expression et facultativement de formulations dudit anticorps, de l'adn codant pour les anticorps et des hôtes comprenant ledit adn..
MA37619A 2012-05-14 2013-05-13 Anticorps anti-fcrn MA37619B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201208370A GB201208370D0 (en) 2012-05-14 2012-05-14 Antibodies
PCT/EP2013/059802 WO2014019727A1 (fr) 2012-05-14 2013-05-13 Anticorps anti-fcrn

Publications (2)

Publication Number Publication Date
MA37619A1 true MA37619A1 (fr) 2016-01-29
MA37619B1 MA37619B1 (fr) 2017-07-31

Family

ID=46458733

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37619A MA37619B1 (fr) 2012-05-14 2013-05-13 Anticorps anti-fcrn

Country Status (44)

Country Link
US (4) US10233243B2 (fr)
EP (3) EP2850101B1 (fr)
JP (4) JP6517140B2 (fr)
KR (2) KR102344901B1 (fr)
CN (1) CN104364265B (fr)
AP (1) AP2014008102A0 (fr)
AR (2) AR091036A1 (fr)
AU (4) AU2013298924B2 (fr)
BR (2) BR112014028457B1 (fr)
CA (2) CA3089517C (fr)
CL (1) CL2014003110A1 (fr)
CO (1) CO7151521A2 (fr)
CY (2) CY1121934T1 (fr)
DK (2) DK3527588T3 (fr)
EA (1) EA032770B1 (fr)
EC (1) ECSP14030789A (fr)
ES (2) ES3004282T3 (fr)
FI (2) FI3527588T3 (fr)
FR (1) FR24C1019I2 (fr)
GB (1) GB201208370D0 (fr)
HR (2) HRP20191334T1 (fr)
HU (3) HUE070274T2 (fr)
IL (1) IL235042B (fr)
LT (3) LT2850101T (fr)
LU (1) LUC00339I2 (fr)
MA (1) MA37619B1 (fr)
ME (1) ME03415B (fr)
MX (1) MX365861B (fr)
NL (1) NL301268I2 (fr)
NZ (1) NZ702457A (fr)
PE (2) PE20150002A1 (fr)
PH (1) PH12014502274A1 (fr)
PL (2) PL3527588T3 (fr)
PT (2) PT2850101T (fr)
RS (2) RS66491B1 (fr)
SG (1) SG11201406625XA (fr)
SI (2) SI3527588T1 (fr)
SM (2) SMT202500037T1 (fr)
TN (1) TN2014000438A1 (fr)
TR (1) TR201910103T4 (fr)
TW (1) TWI598362B (fr)
UA (1) UA118954C2 (fr)
WO (1) WO2014019727A1 (fr)
ZA (1) ZA201407509B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
UA118029C2 (uk) 2013-04-29 2018-11-12 Ф. Хоффманн-Ля Рош Аг Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
SG11201605203UA (en) 2013-12-24 2016-07-28 Argen X N V Fcrn antagonists and methods of use
MX380658B (es) 2014-01-15 2025-03-11 Hoffmann La Roche Variantes de region fc con union mejorada de la proteina a.
US10336825B2 (en) 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
PL3137504T3 (pl) 2014-04-30 2023-10-16 Hanall Biopharma Co., Ltd. Przeciwciało wiążące się z FcRn do leczenia chorób autoimmunologicznych
RS64768B1 (sr) 2015-01-30 2023-11-30 Momenta Pharmaceuticals Inc Fcrn antitela i načini njihove upotrebe
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
EP3294335B1 (fr) 2015-05-12 2023-07-05 Syntimmune Inc. Anticorps anti-fcrn à maturation d'affinité humanisés
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
CN106957365B (zh) 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
CN106957364B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb12及其应用
CN109641045A (zh) * 2016-04-25 2019-04-16 Synt免疫公司 人源化亲和力成熟的抗fcrn抗体
GB201608323D0 (en) * 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
EP4628094A3 (fr) * 2016-06-06 2025-12-31 City of Hope Anticorps baff-r et utilisations de ceux-ci
SMT202400004T1 (it) * 2016-07-29 2024-03-13 Momenta Pharmaceuticals Inc Anticorpi fcrn e loro metodi di utilizzo
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
WO2018119142A1 (fr) 2016-12-21 2018-06-28 Amgen Inc. Formulations d'anticorps anti-tnf alpha
GB201708655D0 (en) * 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
MA49378A (fr) * 2017-06-15 2020-04-22 UCB Biopharma SRL Méthode de traitement de la thrombocytopénie immunitaire
CA3081144A1 (fr) 2017-12-08 2019-06-13 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthenie grave generalisee
KR102904658B1 (ko) 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
US12202900B2 (en) 2018-06-08 2025-01-21 argenx BV Compositions and methods for treating immune thrombocytopenia
CN113518783A (zh) 2018-07-20 2021-10-19 动量制药公司 FcRn抗体组合物
CN113646051A (zh) 2018-10-16 2021-11-12 Ucb生物制药有限责任公司 重症肌无力的治疗方法
KR102886990B1 (ko) * 2018-11-06 2025-11-17 이뮤노반트 사이언시스 게엠베하 항-FcRn 항체를 이용한 그레이브스 안병증의 치료 방법
JP7565951B2 (ja) 2019-06-07 2024-10-11 アルジェニクス ビーブイ 皮下投与に好適なＦｃＲｎインヒビターの医薬製剤
EP4007605A4 (fr) * 2019-08-01 2023-08-16 Momenta Pharmaceuticals, Inc. Anticorps anti-fcrn et leurs procédés d'utilisation
WO2021023619A1 (fr) 2019-08-02 2021-02-11 UCB Biopharma SRL Procédés de purification d'anticorps
JP2023509195A (ja) 2020-01-08 2023-03-07 アルジェニクス ビーブイ 天疱瘡症を治療する方法
WO2021142305A2 (fr) * 2020-01-10 2021-07-15 Coimmune, Inc. Méthodes de traitement de tumeurs
CN114341184B (zh) * 2020-02-10 2023-04-04 北京拓界生物医药科技有限公司 抗FcRn抗体、其抗原结合片段及其医药用途
US20240287191A1 (en) * 2020-06-29 2024-08-29 Hanall Biopharma Co., Ltd. Formulation for anti-fcrn antibody
JP2023550596A (ja) 2020-11-02 2023-12-04 ユーシービー バイオファルマ エスアールエル 運動ニューロン神経変性障害の治療のための抗ｔｒｅｍ１中和抗体の使用
JPWO2023013618A1 (fr) * 2021-08-02 2023-02-09
CN113484526B (zh) * 2021-08-11 2024-08-23 上海迈晋生物医药科技有限公司 一种抗FcRn抗体或其抗原结合片段生物学活性的检测方法
JP7755725B2 (ja) * 2021-08-13 2025-10-16 ジャンスー バイオジェッテイ バイオテクノロジー カンパニー リミテッド Ｆｃｒｎを特異的に認識する抗体およびその使用
CN113912730B (zh) * 2021-12-14 2022-03-04 北京科诺信诚科技有限公司 缓释的抗FcRn抗体或抗原结合片段及其应用
AU2023281650A1 (en) 2022-05-30 2024-10-17 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
CN119698429A (zh) 2022-06-15 2025-03-25 阿根思有限公司 Fcrn结合分子及使用方法
WO2024163894A1 (fr) 2023-02-04 2024-08-08 Momenta Pharmaceuticals, Inc. Compositions et méthodes de traitement d'une maladie hémolytique du fœtus et du nouveau-né
WO2025008537A1 (fr) 2023-07-05 2025-01-09 Ablynx Nv Antagonistes de fcrn améliorés pour le traitement de maladies et de troubles liés à l'igg
TW202527982A (zh) 2023-09-11 2025-07-16 美商默門塔醫藥公司 Fcrn抗體之醫藥組成物
WO2025099576A1 (fr) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions et méthodes de traitement de la polyarthrite rhumatoïde
WO2025163617A1 (fr) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions et méthodes de traitement du syndrome de sjögren
WO2025186787A1 (fr) 2024-03-08 2025-09-12 Momenta Pharmaceuticals, Inc. Compositions et méthodes de traitement de la thrombocytopénie allo-immune fœtale et néonatale
WO2025248017A1 (fr) 2024-05-31 2025-12-04 UCB Biopharma SRL Procédé de purification de protéines de recombinaison
WO2026083290A1 (fr) 2024-10-16 2026-04-23 Momenta Pharmaceuticals, Inc. Compositions et méthodes pour traiter la maladie de sjögren

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2063975C3 (de) 1970-12-28 1973-09-27 Deutsche Vergaser Gmbh & Co Kg, 4040 Neuss Brennstoffzumeßduse mit temperatur abhangig veränderbarem Austrittsquer schnitt fur Vergaser insbesondere Gleich druckvergaser, fur Brennkraftmaschinen
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (fr) 1990-08-02 2002-10-22 John W. Schrader Methodes de production de proteines dotees d'une fonction desiree
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
JP4046354B2 (ja) * 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
WO2002043658A2 (fr) * 2000-11-06 2002-06-06 The Jackson Laboratory Traitement a base de fcrn pour troubles autoimmuns
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
CN101723298B (zh) * 2002-10-04 2013-05-01 岚瑟股份有限公司 多品牌冰镇饮料自动售货机
ES2374068T3 (es) 2002-12-03 2012-02-13 Ucb Pharma, S.A. Ensayo para identificar células productoras de anticuerpos.
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US7662928B2 (en) * 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
CA2534973A1 (fr) * 2003-08-08 2005-02-17 The Research Foundation Of State University Of New York Anti-corps anti-fcrn destines au traitement de troubles auto/allo-immuns
WO2005014655A2 (fr) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugues d'amidon d'hydroxyalkyle et de proteine
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
WO2006040153A2 (fr) 2004-10-13 2006-04-20 Ablynx N.V. Nanocorps™ contre la proteine beta-amyloide et polypeptides les renfermant pour le traitement de maladies degeneratives neurales, telles que la maladie d'alzheimer
GB0506912D0 (en) * 2005-04-05 2005-05-11 Celltech R&D Ltd Biological products
CA2606378A1 (fr) 2005-04-29 2006-11-09 The Jackson Laboratory Anticorops de fcrn et utilisations
WO2006130834A2 (fr) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System Molecules d'immunoglobuline ayant des proprietes ameliorees
ZA200801154B (en) * 2005-07-21 2009-07-29 Genmab As Potency assays for antibody drug substance binding to an FC receptor
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
ZA200804337B (en) * 2005-11-28 2009-11-25 Genmab As Recombinant monovalent antibodies and methods for production thereof
CA2637929A1 (fr) * 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anticorps anti-fcrn utilises dans le traitement d'etats auto/allo-immuns
TW200745163A (en) * 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
TW200911289A (en) 2007-08-09 2009-03-16 Syntonix Pharmaceuticals Inc Immunomodulatory peptides
EP2535349A1 (fr) 2007-09-26 2012-12-19 UCB Pharma S.A. Fusions d'anticorps à double spécificité
WO2009080764A2 (fr) * 2007-12-20 2009-07-02 Abylnx N.V. Administration orale ou nasale de composés comprenant des séquences d'acides aminés
WO2009131702A2 (fr) * 2008-04-25 2009-10-29 Dyax Corp. Protéines de liaison au récepteur fc
WO2010014909A1 (fr) 2008-08-01 2010-02-04 Syntonix Pharmaceuticals, Inc. Peptides immunomodulateurs
CA2737241C (fr) 2008-09-26 2017-08-29 Ucb Pharma S.A. Proteines de fusion d'anticorps multivalentes
WO2011030107A1 (fr) 2009-09-10 2011-03-17 Ucb Pharma S.A. Anticorps multivalents
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
AU2012262007B2 (en) 2011-06-02 2017-06-22 Takeda Pharmaceutical Company Limited Fc receptor binding proteins
WO2013068571A1 (fr) 2011-11-11 2013-05-16 Ucb Pharma S.A. Anticorps se liant à l'albumine et leurs fragments de liaison
KR20130071961A (ko) 2011-12-21 2013-07-01 한올바이오파마주식회사 ＦｃＲｎ 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products

Also Published As

Publication number Publication date
ES2732081T3 (es) 2019-11-20
CY2024011I2 (el) 2024-12-13
AU2013298924B2 (en) 2018-05-10
TWI598362B (zh) 2017-09-11
DK2850101T3 (da) 2019-07-15
CY1121934T1 (el) 2020-10-14
US11384148B2 (en) 2022-07-12
UA118954C2 (uk) 2019-04-10
US20230074381A1 (en) 2023-03-09
CA2872326C (fr) 2020-10-13
IL235042B (en) 2019-05-30
CO7151521A2 (es) 2014-12-29
LUC00339I2 (fr) 2026-03-04
GB201208370D0 (en) 2012-06-27
KR20210014761A (ko) 2021-02-09
SMT201900425T1 (it) 2019-11-13
CA3089517C (fr) 2022-10-04
US20150118240A1 (en) 2015-04-30
JP2018183151A (ja) 2018-11-22
PH12014502274B1 (en) 2014-12-10
MX2014012890A (es) 2014-11-14
JP7050115B2 (ja) 2022-04-07
JP7221000B2 (ja) 2023-02-13
ME03415B (fr) 2020-01-20
AU2018205057B9 (en) 2020-10-22
EP2850101A1 (fr) 2015-03-25
HK1204627A1 (en) 2015-11-27
EP2850101B1 (fr) 2019-05-01
IL235042A0 (en) 2014-12-31
HUS2400016I1 (hu) 2024-06-28
ES3004282T3 (en) 2025-03-12
HRP20250195T1 (hr) 2025-04-11
ECSP14030789A (es) 2015-09-30
EP3527588A1 (fr) 2019-08-21
AU2013298924A1 (en) 2015-01-15
NZ702457A (en) 2016-09-30
EP4509189A3 (fr) 2025-05-21
HUE045012T2 (hu) 2019-11-28
AU2018205057B2 (en) 2020-05-21
CA2872326A1 (fr) 2014-02-06
TR201910103T4 (tr) 2019-08-21
AR132144A2 (es) 2025-05-28
AR091036A1 (es) 2014-12-30
AU2018205057A1 (en) 2018-07-26
JP2015525204A (ja) 2015-09-03
ZA201407509B (en) 2016-02-24
LT2850101T (lt) 2019-08-12
PH12014502274A1 (en) 2014-12-10
JP6517140B2 (ja) 2019-05-22
MX365861B (es) 2019-06-18
SI3527588T1 (sl) 2025-04-30
PT2850101T (pt) 2019-07-23
FR24C1019I1 (fr) 2024-07-19
HUE070274T2 (hu) 2025-05-28
SG11201406625XA (en) 2014-12-30
US12338285B2 (en) 2025-06-24
RS59072B1 (sr) 2019-09-30
CY2024011I1 (el) 2024-12-13
JP2022104938A (ja) 2022-07-12
PL3527588T3 (pl) 2025-04-07
EA201492101A1 (ru) 2015-04-30
FIC20240017I1 (fi) 2024-06-03
EA032770B1 (ru) 2019-07-31
FR24C1019I2 (fr) 2025-03-28
KR102253090B1 (ko) 2021-05-18
NL301268I2 (nl) 2024-05-15
FI3527588T3 (fi) 2025-03-05
HRP20191334T1 (hr) 2019-10-18
US10233243B2 (en) 2019-03-19
SMT202500037T1 (it) 2025-03-12
TN2014000438A1 (en) 2016-03-30
BR122020023791B1 (pt) 2023-04-04
JP2020168003A (ja) 2020-10-15
AU2024202395A1 (en) 2024-05-16
AP2014008102A0 (en) 2014-12-31
TW201350505A (zh) 2013-12-16
US20190248890A1 (en) 2019-08-15
BR112014028457B1 (pt) 2023-04-04
WO2014019727A1 (fr) 2014-02-06
RS66491B1 (sr) 2025-03-31
DK3527588T3 (da) 2025-02-10
LT3527588T (lt) 2025-02-25
LTPA2024515I1 (fr) 2024-06-10
BR112014028457A2 (pt) 2017-06-27
CN104364265B (zh) 2019-07-16
EP3527588B1 (fr) 2025-01-15
CA3089517A1 (fr) 2014-02-06
PE20150002A1 (es) 2015-01-28
MA37619B1 (fr) 2017-07-31
PL2850101T3 (pl) 2019-10-31
AU2020217370A1 (en) 2020-09-03
KR20150005987A (ko) 2015-01-15
JP7485712B2 (ja) 2024-05-16
CL2014003110A1 (es) 2015-06-19
LTC2850101I2 (fr) 2025-11-10
KR102344901B1 (ko) 2021-12-28
US20250346672A1 (en) 2025-11-13
CN104364265A (zh) 2015-02-18
SI2850101T1 (sl) 2019-08-30
EP4509189A2 (fr) 2025-02-19
PE20190229A1 (es) 2019-02-13
PT3527588T (pt) 2025-01-24

Similar Documents

Publication Publication Date Title
MA37619B1 (fr) Anticorps anti-fcrn
MA39096B1 (fr) Anticorps spécifiques à fcrn
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
MA37538A2 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
EA201301180A1 (ru) Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой
WO2015109124A3 (fr) Agents immunomodulateurs
MY156286A (en) Human il-23 antigen binding proteins
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
MA44922A1 (fr) Anticorps
EA201401204A1 (ru) Антитела к il-23p19
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
MY199321A (en) Oncostatin m receptor antigen binding proteins
MX366178B (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
PH12014502182A1 (en) Methods and compositions for modulating notch activity
MA35947B1 (fr) Anticorps et immunoconjugués anti-lgr5